Early Proof-of-Concept and Platform Potential Drive Buy Rating on Krystal Biotech Despite Pending Lung Function Data
I'm PortAI, I can summarize articles.
William Blair analyst Sami Corwin has maintained a Buy rating on Krystal Biotech (KRYS) due to promising early data and platform potential. He highlights encouraging results from KB407 in cystic fibrosis, showing effective CFTR delivery and expression. Despite the lack of lung function data, Corwin believes that achieving one-third cell expression could lead to functional improvements. He awaits further results from the CORAL-3 trial to assess efficacy. TipRanks also reiterated a Buy rating with a $282 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments